Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | THRA | P10827 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.34 |
| ▸ | FAAH | O00519 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9945974 | 0.85 | ESR1 (0.38) | CYP1A2CYP2C9CYP2C19GLASMN1; SMN2 | |
| SCHEMBL12360648 | 0.84 | L3MBTL1 (0.40) | CYP1A2CYP2C19SMN1; SMN2L3MBTL1TDP1 | |
| SCHEMBL9945975 | 0.84 | GRM2 (0.37) | CYP1A2CYP2C9CYP2C19GLASMN1; SMN2 | |
| SCHEMBL15131365 | 0.80 | L3MBTL1 (0.46) | CYP1A2CYP2C9CYP2C19GLASMN1; SMN2 | |
| SCHEMBL15120786 | 0.80 | CYP1A2 (0.50) | CYP1A2CYP2C9CYP2C19GLASMN1; SMN2 | |
| SCHEMBL18374607 | 0.79 | CYP1A2 (0.41) | CYP1A2CYP2C9CYP2C19GLASMN1; SMN2 | |
| SCHEMBL12967735 | 0.77 | CYP1A2 (0.42) | CYP1A2CYP2C9CYP2C19GLASMN1; SMN2 | |
| SCHEMBL11994372 | 0.77 | FAAH (0.43) | CYP1A2CYP2C9CYP2C19GLASMN1; SMN2 | |
| SCHEMBL24661358 | 0.76 | CYP1A2 (0.47) | CYP1A2CYP2C9CYP2C19GLASMN1; SMN2 | |
| SCHEMBL15120819 | 0.76 | L3MBTL1 (0.53) | CYP1A2CYP2C9CYP2C19GLASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | CYP1A2 2891/4885CYP2C9 4298/4885CYP2C19 3767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.